大洋洲 · 综合新闻 · The Courier-Mail
Recce topical gel shows strong diabetic foot infection efficacy ahead of Phase III data review
A review of blinded data from Recce Pharmaceuticals’ Phase III trial in Indonesia of RECCE 327 Gel (R327G) in diabetic foot infections (DFIs) by clinical experts and a…
在 The Courier-Mail 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.couriermail.com.au)
